Patents by Inventor Alan Naylor
Alan Naylor has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240051961Abstract: The present invention relates to compounds of formula (I) as GPR65 modulators for the treatment of a proliferative disorder, such as e.g. cancer, an immune disorder, asthma, chronic obstructive pulmonary disease (CORD) or acute respiratory distress syndrome (ARDS). Preferred compounds are e.g. N-(Pyridin-2-yl)-6,7,8,9-tetrahydro-5H-5,8-epiminocyclohepta[c]pyridine-10-carboxamide derivatives and similar compounds, such as e.g.Type: ApplicationFiled: December 17, 2021Publication date: February 15, 2024Inventors: Tom MCCARTHY, Alan NAYLOR, Gavin MILNE, David MILLER, Maria IEVA
-
Publication number: 20230373989Abstract: One aspect of the invention relates to a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, (I) wherein: ring A is a 5 or 6 membered aromatic or heteroaromatic ring, wherein said aromatic or heteroaromatic ring is optionally substituted with one or more substituents selected from F, Cl, Br, I, CN, alkoxy, NR11R11?, OH, alkyl, haloalkyl, aralkyl, aryl, and heteroaryl, and wherein said aryl and heteroaryl substituents are in turn optionally substituted with one or more substituents each independently selected from F, Cl, Br, I, CN, alkoxy, NR11R11?, OH, alkyl, haloalkyl, and aralkyl; Y is selected from C?N—OH and CR10R10?, wherein R10 and R10?, are each independently selected from H, F, alkyl, and haloalkyl; R1, R4, and R5 are each independently selected from H, F, Cl, Br, and I; R2 and R3 are each independently selected from H, F, Cl, Br, I, CN, methoxy, and haloalkyl; and R11 and R11? wherein R12 and R13 are both alkyl; for use as a medicament.Type: ApplicationFiled: June 4, 2021Publication date: November 23, 2023Inventors: Tom MCCARTHY, Gavin MILNE, Tobias MOECHEL, Alan NAYLOR, David MILLER
-
Patent number: 11787906Abstract: A drug-polymer conjugate, which is a copolymer of at least one monomer of formula (I): (I) where: X may be the same or different at each occurrence and represents a terminal functional group comprising an alkyne or an azide; Q is independently selected at each occurrence and may be present or absent and when present, represents a linking group; R is selected from the group consisting of linear or branched hydrocarbon, optionally substituted aryl and optionally substituted heteroaryl; D is a releasable drug selected from prostaglandins, ?-blockers and mixtures thereof; L is a linker group group; and at least one co-monomer of Formula III III J represents a linking functional group, n is 2 to 8, preferably 3 to 8; Y comprises a polyether of formula (ORa)m wherein Ra is independently ethylene, propylene and butylene and m is from 1 to 300 (preferably 2 to 300) and the polyether is in chain with one or more groups which are preferably selected from one or more of optionally substituted straight or branched C1 toType: GrantFiled: March 14, 2018Date of Patent: October 17, 2023Assignee: POLYACTIVA PTY LTDInventors: Stephen Lonsdale Birkett, Andrew Craig Donohue, Asha Marina D'Souza, Sarah Man Yee Ng, Adrian Sulistio, Russell John Tait, David Valade, Alan Naylor, Jason Watling, Carmen Vittoria Scullino
-
Patent number: 11696955Abstract: A polymer-prostaglandin conjugate comprising: a polymer backbone comprising a plurality of moieties of formula (I): where: T represents a triazole moiety; Q is independently selected at each occurrence and may be present or absent and when present represents a linking group; R is selected from the group consisting of linear or branched hydrocarbon; D is selected from prostaglandins; and L is a group of formula (II) wherein R5 is selected from hydrogen and C1 to C6 alkyl; (R) indicates the end of the group bonded to the R group; and (D) indicates the end of the group attached to the group D.Type: GrantFiled: December 23, 2021Date of Patent: July 11, 2023Assignee: POLYACTIVA PTY LTDInventors: Stephen Lonsdale Birkett, Andrew Craig Donohue, Asha Marina D'Souza, Sarah Man Yee Ng, Adrian Sulistio, Russell John Tait, David Valade, Alan Naylor, Jason Watling
-
Publication number: 20230174530Abstract: The present invention relates to a compound of formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, (I) wherein: ring A is a 5- or 6-membered monocyclic aromatic or heteroaromatic ring, or a 9- or 10-membered bicyclic aromatic or heteroaromatic ring, each of which is optionally substituted with one or more substituents selected from F, Cl, Br, I, CN, alkoxy, NR11R11?, OH, SO2-alkyl, CO2-alkyl, alkyl, haloalkyl, aralkyl, aryl, and heteroaryl, and wherein said aryl and heteroaryl substituents are in turn optionally substituted with one or more substituents each independently selected from F, Cl, Br, I, CN, alkoxy, NR11R11?, OH, alkyl, haloalkyl, and aralkyl; Y and Z are each independently CR10R10?, wherein R10 and R10? are each independently selected from H, F, alkyl, and haloalkyl; R1, R4, and R5 are each independently selected from H, F, Cl, Br, I and haloalkyl; R2 and R3 are each independently selected from H, F, Cl, Br, I, CN, and haloalkyl; wherein at least two of R2, R3 and R4 are otherType: ApplicationFiled: June 4, 2021Publication date: June 8, 2023Inventors: Tom MCCARTHY, Gavin MILNE, Tobias MOECHEL, Alan NAYLOR
-
Publication number: 20220401455Abstract: A drug-polymer conjugate, which is a copolymer of at least one monomer of formula (I) where: X may be the same or different at each occurrence and represents a terminal functional group comprising an alkyne or an azide; Q is independently selected at each occurrence and may be present or absent and when present, represents a linking group; R is selected from the group consisting of linear or branched hydrocarbon, optionally substituted aryl and optionally substituted heteroaryl; D is a releasable bicyclic prostaglandin; L is a linker group; and at least one co-monomer of Formula III J-(Y1-A)n, J represents a linking functional group, n is 2 to 8 preferably 3 to 8; Y1 comprises a polyether of formula (ORa)m wherein Ra is independently ethylene, propylene and butylene and m is from 1 to 300 (preferably 2 to 300) and the polyether is in chain with one or more groups which are preferably selected from one or more of optionally substituted straight or branched C1 to C10 alkylene, amino, ether, ester, amide, carbonType: ApplicationFiled: September 19, 2019Publication date: December 22, 2022Applicant: POLYACTIVA PTY LTDInventors: Stephen Lonsdale BIRKETT, Andrew Craig DONOHUE, Asha Marina D'SOUZA, Sarah Man Yee NG, Adrian SULISTIO, Russell John TAIT, David VALADE, Alan NAYLOR, Jason WATLING, Carmen Vittoria SCULLINO
-
Publication number: 20220305011Abstract: This invention relates to compounds of formula (I) and methods of treatment using the compounds. The invention also relates to processes and methods for producing the compounds of the invention. The compounds of the invention are modulators of Factor XII (e.g. Factor XIIa). In particular, the compounds are inhibitors of Factor XIIa and may be useful as anticoagulants.Type: ApplicationFiled: March 28, 2019Publication date: September 29, 2022Inventors: Helen PHILIPPOU, Richard POSTER, Colin FISHWICK, Charlotte REVILL, Ian YULE, Roger TAYLOR, Alan NAYLOR, Philip Spencer FALLON, Stuart CROSBY, Anna HOPKINS, Lucie Juliette GUETZOYAN, Alistair James MACNAIR, Mark Richard STEWART, Natalie Louise WINFIELD
-
Publication number: 20220226483Abstract: A polymer-prostaglandin conjugate comprising: a polymer backbone comprising a plurality of moieties of formula (I): where: T represents a triazole moiety; Q is independently selected at each occurrence and may be present or absent and when present represents a linking group; R is selected from the group consisting of linear or branched hydrocarbon; D is selected from prostaglandins; and L is a group of formula (II) wherein R5 is selected from hydrogen and C1 to C6 alkyl; (R) indicates the end of the group bonded to the R group; and (D) indicates the end of the group attached to the group D.Type: ApplicationFiled: December 23, 2021Publication date: July 21, 2022Applicant: POLYACTIVA PTY LTDInventors: Stephen Lonsdale BIRKETT, Andrew Craig DONOHUE, Asha Marina D'SOUZA, Sarah Man Yee NG, Adrian SULISTIO, Russell John TAIT, David VALADE, Alan NAYLOR, Jason WATLING
-
Patent number: 11207417Abstract: A polymer-prostaglandin conjugate comprising: a polymer backbone comprising a plurality of moieties of formula (I): where: T represents a triazole moiety; Q is independently selected at each occurrence and may be present or absent and when present represents a linking group; R is selected from the group consisting of linear or branched hydrocarbon; D is selected from prostaglandins; and L is a group of formula (II) wherein R5 is selected from hydrogen and C1 to C6 alkyl; (R) indicates the end of the group bonded to the R group; and (D) indicates the end of the group attached to the group D.Type: GrantFiled: March 14, 2018Date of Patent: December 28, 2021Assignee: POLYACTIVA PTY LTDInventors: Stephen Lonsdale Birkett, Andrew Craig Donohue, Asha Marina D'Souza, Sarah Man Yee Ng, Adrian Sulistio, Russell John Tait, David Valade, Alan Naylor, Jason Watling
-
Publication number: 20210087172Abstract: This invention relates to compounds of formula (I). The compounds of formula (I) are modulators of Factor XII, specifically Factor XIIa. The compounds are inhibitors of Factor XIIa and may be useful as anticoagulants. The compounds of formula (I) may be used in methods of treatment (or prevention) of blood disorders related to bleeding or coagulation.Type: ApplicationFiled: April 29, 2019Publication date: March 25, 2021Inventors: Helen PHILIPPOU, Richard FOSTER, Colin FISHWICK, Charlotte REVILL, Ian YULE, Roger TAYLOR, Alan NAYLOR, Philip Spencer FALLON, Stuart CROSBY, Anna HOPKINS, Mark Richard STEWART, Natalie Louise WINFIELD
-
Publication number: 20210070708Abstract: The invention is directed to compounds of general formula (I) and pharmaceutical compositions containing such compounds. The compounds and compositions have valuable pharmaceutical properties. In particular, they may be used for the treatment of cancer. Novel intermediates and novel methods of preparation are also disclosed.Type: ApplicationFiled: July 14, 2020Publication date: March 11, 2021Applicant: BerGenBio ASAInventors: Jason John Shiers, John Paul Watts, Stuart Thomas Onions, Mohammed Abdul Quddus, Joseph William Wrigglesworth, Colin Peter Sambrook-Smith, Alan Naylor, Derek Londesbrough
-
Patent number: 10766861Abstract: The invention is directed to compounds of general formula (I) and pharmaceutical compositions containing such compounds. The compounds and compositions have valuable pharmaceutical properties. In particular, they may be used for the treatment of cancer. Novel intermediates and novel methods of preparation are also disclosed.Type: GrantFiled: May 15, 2019Date of Patent: September 8, 2020Assignee: BerGenBio ASAInventors: Jason John Shiers, John Paul Watts, Stuart Thomas Onions, Mohammed Abdul Quddus, Joseph William Wrigglesworth, Colin Peter Sambrook-Smith, Alan Naylor, Derek Londesbrough
-
Patent number: 10758626Abstract: The present invention relates in general to polymer-bioactive agent conjugates for delivering a bioactive agent to a subject. The polymer-bioactive agent conjugates contain triazole moieties in the polymer backbone and a bioactive moiety selected from quinolones, NSAIDs and mixtures thereof. The present invention also relates to methods for preparing the polymer conjugates using click cycloaddition chemical reactions, to monomer-bioactive agent conjugates suitable for preparing the polymer conjugates, and to pharmaceutical products comprising the polymer conjugates for the post-surgical care to treat or prevent infections, provide analgesia and treat inflammation.Type: GrantFiled: September 9, 2016Date of Patent: September 1, 2020Assignee: POLYACTIVA PTY LTDInventors: Stephen Lonsdale Birkett, Andrew Craig Donohue, Asha Marina D'Souza, Sarah Man Yee Ng, Adrian Sulistio, Russell John Tait, David Valade, Alan Naylor, Anton Blencowe
-
Publication number: 20200123322Abstract: A drug-polymer conjugate, which is a copolymer of at least one monomer of formula (I): (I) where: X may be the same or different at each occurrence and represents a terminal functional group comprising an alkyne or an azide; Q is independently selected at each occurrence and may be present or absent and when present, represents a linking group; R is selected from the group consisting of linear or branched hydrocarbon, optionally substituted aryl and optionally substituted heteroaryl; D is a releasable drug selected from prostaglandins, ?-blockers and mixtures thereof; L is a linker group group; and at least one co-monomer of Formula III III J represents a linking functional group, n is 2 to 8, preferably 3 to 8; Y comprises a polyether of formula (ORa)m wherein Ra is independently ethylene, propylene and butylene and m is from 1 to 300 (preferably 2 to 300) and the polyether is in chain with one or more groups which are preferably selected from one or more of optionally substituted straight or branched Ci toType: ApplicationFiled: March 14, 2018Publication date: April 23, 2020Applicant: POLYACTIVA PTY LTDInventors: Stephen Lonsdale BIRKETT, Andrew Craig DONOHUE, Asha Marina D'SOUZA, Sara Man Yee NG, Adrian SULISTIO, Russell John TAIT, David VALADE, Alan NAYLOR, Jason WATLING, Carmen Vittoria SCULLINO
-
Publication number: 20200121798Abstract: A polymer-prostaglandin conjugate comprising: a polymer backbone comprising a plurality of moieties of formula (I): where: T represents a triazole moiety; Q is independently selected at each occurrence and may be present or absent and when present represents a linking group; R is selected from the group consisting of linear or branched hydrocarbon; D is selected from prostaglandins; and L is a group of formula (II) wherein R5 is selected from hydrogen and C1 to C6 alkyl; (R) indicates the end of the group bonded to the R group; and (D) indicates the end of the group attached to the group D.Type: ApplicationFiled: March 14, 2018Publication date: April 23, 2020Applicant: POLYACTIVA PTY LTDInventors: Stephen Lonsdale BIRKETT, Andrew Craig DONOHUE, Asha Marina D'SOUZA, Sara Man Yee NG, Adrian SULISTIO, Russell John TAIT, David VALADE, Alan NAYLOR, Jason WATLING
-
Publication number: 20200010421Abstract: The invention is directed to compounds of general formula (I) and pharmaceutical compositions containing such compounds. The compounds and compositions have valuable pharmaceutical properties. In particular, they may be used for the treatment of cancer. Novel intermediates and novel methods of preparation are also disclosed.Type: ApplicationFiled: May 15, 2019Publication date: January 9, 2020Applicant: BerGenBio ASAInventors: Jason John Shiers, John Paul Watts, Stuart Thomas Onions, Mohammed Abdul Quddus, Joseph William Wrigglesworth, Colin Peter Sambrook-Smith, Alan Naylor, Derek Londesbrough
-
Patent number: 10370388Abstract: The present invention relates to heterocyclic compounds useful for antagonizing angiotensin II Type 2 (AT2) receptor. More particularly the invention relates to pyrrolidine and azetidine compounds, compositions containing them and their use in methods of treating or preventing disorders or diseases associated with AT2 receptor function including neuropathic pain, inflammatory pain, conditions associated with neuronal hypersensitivity, impaired nerve conduction velocity, cell proliferation disorders, disorders associated with an imbalance between bone resorption and bone formation and disorders associated with aberrant nerve regeneration.Type: GrantFiled: February 6, 2017Date of Patent: August 6, 2019Assignee: NOVARTIS AGInventors: Thomas David McCarthy, Alan Naylor
-
Patent number: 10336702Abstract: The invention is directed to compounds of general formula (I), and pharmaceutical compositions containing such compounds. The compounds and compositions have valuable pharmaceutical properties. In particular, they may be used for the treatment of cancer. Novel intermediates and novel methods of preparation are also disclosed.Type: GrantFiled: December 23, 2015Date of Patent: July 2, 2019Assignee: BerGenBio ASAInventors: Jason John Shiers, John Paul Watts, Stuart Thomas Onions, Mohammed Abdul Quddus, Joseph William Wrigglesworth, Colin Peter Sambrook-Smith, Alan Naylor, Derek Londesbrough
-
Patent number: 10308628Abstract: The present invention relates to heterocyclic compounds useful for antagonising angiotensin II Type 2 (AT2) receptor. More particularly the invention relates to compounds of formula (I), as described herein, compositions containing them and their use in methods of treating or preventing disorders or diseases associated with AT2 receptor function including neuropathic pain, inflammatory pain, conditions associated with neuronal hypersensitivity, impaired nerve conduction velocity, cell proliferation disorders, disorders associated with an imbalance between bone resorption and bone formation and disorders associated with aberrant nerve regeneration.Type: GrantFiled: March 9, 2016Date of Patent: June 4, 2019Assignee: NOVARTIS AGInventors: Jane Brown, Thomas David McCarthy, Alan Naylor, John Paul Watts
-
Patent number: 10272652Abstract: A sheet of heat shrink laminated composite for use creating repair patches for repairing or building up a surface formed of a composite material such as fiberglass-reinforced plastic. The sheet includes first and second layers of a heat-curable adhesive. The sheet includes a reinforcement layer sandwiched between the first and second layers of the adhesive. The sheet further includes a pressure application layer, which is formed of a heat-activated shrink wrap film, abutting an outer surface of the first layer of the adhesive. The reinforcement layer may include a sheet of a porous fabric or cloth, which may be fibers of carbon or glass such as unidirectional e-glass fibers. The adhesive is cured when heated to a temperature in a curing temperature range, and the shrink wrap film is activated when heated to a temperature in an activation temperature range that overlaps the curing temperature range of the adhesive.Type: GrantFiled: August 12, 2015Date of Patent: April 30, 2019Assignee: DISNEY ENTERPRISES, INC.Inventors: Laurel Lindsey Skaggs, Mark E. Tripp, Mark Alan Naylor